Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NH140068
- Development stage
- Phase 1
- Lead developer
- Jiangsu Nhwa Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NH140068 is a novel small molecule antipsychotic developed by Jiangsu Enhua Pharmaceutical for the treatment of schizophrenia. It is designed as a multi-target ligand with a pharmacological profile characterized by partial agonism at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonism at serotonin 5-HT2A receptors. This balanced activity aims to provide efficacy against both positive and negative symptoms of schizophrenia while minimizing common side effects such as extrapyramidal symptoms (EPS) and metabolic disturbances. The drug is currently undergoing clinical evaluation in China, where it has progressed into Phase 2 trials.
Beyond the preview
Go deeper on NH140068.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NH140068.